Literature DB >> 15101565

Treatment modalities among US children diagnosed with attention-deficit hyperactivity disorder: 1995-99.

Linda M Robison1, David A Sclar, Tracy L Skaer, Richard S Galin.   

Abstract

The objective of this study was to determine the prevalence of single and combination treatment modalities among US children aged 5-18 years who were diagnosed with attention-deficit hyperactivity disorder (ADHD). Treatments included: (i) stimulant pharmacotherapy alone; (ii) psychotherapy and/or mental health counselling alone; (ii) a combination; or (iv) no treatment. Data from the US National Ambulatory Medical Care Survey (NAMCS) for the years 1995-99, were used for this analysis. Office-based physician-patient visits documenting a recorded diagnosis of ADHD (ICD-9-CM codes 314.00 or 314.01) were extracted from the NAMCS. Findings are presented for children diagnosed with ADHD with or without comorbid mental illness, for children diagnosed with ADHD without comorbid mental illness, by gender, and by age groups. Over the timeframe 1995-99, an estimated 14 402 090 office-based visits documented a diagnosis of ADHD, with (24%) or without (76%) comorbid mental illness, among children aged 5-18 years. Overall, the most frequent treatment was stimulant medication alone (42.0%). This was followed by the combination treatment of stimulant medication plus psychotherapy and/or mental health counselling (32.1%). Only 10.8% of the children received psychotherapy and/or mental health counselling alone; 15.1% received no treatment beyond the office-based visit. This pattern was consistent for boys and girls; however, a larger proportion of boys (11.7%) were receiving psychotherapy and/or mental health counselling alone than girls (8.2%). More girls (18.7%) were receiving no treatment option compared to boys (13.9%). The percentage of children receiving psychotherapy and/or mental health counselling alone increased with each age group (6.7%, 5-8 years; 11.3%, 9-12 years; 13.6%, 13-18 years), as did the combination treatment of stimulant medication plus psychotherapy and/or mental health counselling (28.2%, 31%, 37.3%, respectively). Only 8.2% of children age 13-18 years were receiving no treatment option compared to 16.9% of children age 9-12 years, and 19.5% of those aged 5-8 years. The reasons for the gender and age group differences discerned in this study require further investigation, as does the reason why 15.1% of children were receiving no treatment beyond the office-based visit.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15101565     DOI: 10.1097/00004850-200401000-00003

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  4 in total

1.  Association of traumatic brain injury in childhood and attention-deficit/hyperactivity disorder: a population-based study.

Authors:  Ling-Yu Yang; Chao-Ching Huang; Wen-Ta Chiu; Li-Tung Huang; Wei-Cheng Lo; Jia-Yi Wang
Journal:  Pediatr Res       Date:  2016-04-11       Impact factor: 3.756

2.  Hypericum perforatum (St John's wort) for attention-deficit/hyperactivity disorder in children and adolescents: a randomized controlled trial.

Authors:  Wendy Weber; Ann Vander Stoep; Rachelle L McCarty; Noel S Weiss; Joseph Biederman; Jon McClellan
Journal:  JAMA       Date:  2008-06-11       Impact factor: 56.272

3.  Sex differences in effectiveness of extended-release stimulant medication among adolescents with attention-deficit/hyperactivity disorder.

Authors:  Amori Yee Mikami; Daniel J Cox; Margaret T Davis; H Kent Wilson; R Lawrence Merkel; Roger Burket
Journal:  J Clin Psychol Med Settings       Date:  2009-05-06

4.  Co-morbidity and patterns of care in stimulant-treated children with ADHD in the Netherlands.

Authors:  Adrianne Faber; Luuk J Kalverdijk; Lolkje T W de Jong-van den Berg; Jacqueline G Hugtenburg; Ruud B Minderaa; Hilde Tobi
Journal:  Eur Child Adolesc Psychiatry       Date:  2009-11-06       Impact factor: 4.785

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.